Living with advanced or metastatic triple-negative breast cancer is incredibly difficult. Because this specific type of cancer can be aggressive, finding the right combination of treatments is vital for managing the disease and improving patient outcomes.
A review of data from 523 patients looked at what happens when doctors add targeted therapy to a standard chemotherapy regimen. The results showed that patients receiving both treatments had significantly higher objective response rates and better disease control compared to those who received only chemotherapy. This means the tumors responded more effectively to the combined treatment.
While the combination showed promise in controlling the cancer, the evidence is still early. The improvement in progression-free survival was not statistically significant, and there was not enough data to confirm if the combination helped patients live longer overall. Additionally, no significant increase in adverse events was observed with the added therapy. Because of the limited number of studies available, more research is needed to confirm these findings.
